natgillin/translations-raw huggingface dataset:
allowing the latches to return from their idle position to their fixing position whereby engaging the catching means (33, 33a) of each latch in the corresponding fixing means (31, 31a) to couple the ladle shroud to the collector nozzle, 
omogućavanje da se zasuni vrate iz položaja praznog hoda u njihov položaj za pričvršćenje, pri čemu zahvaćaju sredstva za zahvaćanje (33, 33a) svakog zasuna u odgovarajućim sredstvima za pričvršćivanje (31, 31a) radi spajanja izljevnika na mlaznicu kolektora, e) otpuštanje zahvata na izljevniku.
releasing the grip on the ladle shroud. Method for reversibly coupling a ladle shroud (111) to a collector nozzle (112) of a ladle (11), said method comprising providing a kit of parts according to claim 14 and carrying out the following steps with the robot, 
Postupak za reverzibilno spajanje izljevnika (111) na mlaznicu kolektora (112) lonca (11), pri čemu taj postupak obuhvaća pripremu kompleta dijelova u skladu s patentnim zahtjevom 14 i provođenje slijedećih koraka robotom,
allowing the latches to return from their idle position to their fixing position whereby engaging the catching means (33, 33a) of each latch in the corresponding fixing means (31, 31a) to couple the ladle shroud to the collector nozzle, 
omogućavanje da se zasuni vrate iz položaja praznog hoda u njihov položaj za pričvršćenje, pri čemu zahvaćaju sredstva za zahvaćanje (33, 33a) svakog zasuna u odgovarajućim sredstvima za pričvršćivanje (31, 31a) radi spajanje izljevnika na mlaznicu kolektora,
releasing the grip on the ladle shroud. 
otpuštanje zahvata na izljevniku.
A radioactive metal-labeled anti-P-cadherin antibody, which is obtained by binding a radioactive metallic element to an anti-P-cadherin antibody via a metal-chelating reagent, wherein the anti-P-cadherin antibody is a monoclonal antibody or a recombinant antibody produced by an antibody-producing cell represented by an accession number of NITE BP-897, NITE BP-899, NITE BP-1048, NITE BP-1049, or NITE BP-1050, or a P-cadherin binding fragment of any of these antibodies. 
Anti-P-kadherin antitijelo obilježeno radioaktivnim metalima, naznačeno time, da se dobiva vezanjem radioaktivnog metalnog elementa na anti-P-kadherin antitijelo putem reagensa za keliranje metala, pri čemu je anti-P-kadherin antitijelo monoklonsko antitijelo ili rekombinantno antitijelo proizvedeno pomoću stanice koja proizvodi antitijela predstavljene s pristupnim brojem NITE BP-897, NITE BP-899, NITE BP-1048, NITE BP-1049 ili NITE BP-1050, ili fragment koji veže P-kadherin bilo kojeg od ovih antitijela.
The radioactive metal-labeled anti-P-cadherin antibody according to claim 1 or 2, wherein the metal-chelating reagent is selected from the group consisting of isothiocyanobenzyl DOTA, methylisothiocyanobenzyl DTPA, and cyclohexylisothiocyanobenzyl DTPA. 
Anti-P-kadherin antitijelo obilježeno radioaktivnim metalima u skladu s patentnim zahtjevom 1 ili 2, naznačeno time, da je reagens za keliranje metala odabran iz skupine koju čine izotiocijanobenzil DOTA, metilizotiocijanobenzil DTPA i cikloheksilizotiocijanobenzil DTPA.
A DOTA-bound anti-P-cadherin antibody, which is obtained by reacting an anti-P-cadherin antibody with isothiocyanobenzyl DOTA, wherein the anti-P-cadherin antibody is a monoclonal antibody or recombinant antibody produced by an antibody-producing cell represented by an accession number of NITE BP-897, NITE BP-899, NITE BP-1048, NITE BP-1049, or NITE BP-1050, or a P-cadherin binding fragment of any of these antibodies. 
DOTA-vezano anti-P-kadherin antitijelo, naznačeno time, da se dobiva reakcijom anti-P-kadherin antitijela s izotiocijanobenzil DOTA, pri čemu je anti-P-kadherin antitijelo monoklonsko antitijelo ili rekombinantno antitijelo proizvedeno pomoću stanice koja proizvodi antitijela predstavljene s pristupnim brojem NITE BP-897, NITE BP-899, NITE BP-1048, NITE BP-1049 ili NITE BP-1050, ili fragment koji veže P-kadherin bilo kojeg od tih antitijela.
A method of producing the anti-human NGF antibody Fab' fragment, comprising expressing an anti-human NGF antibody Fab' fragment by culturing a host cell selected from a group consisting of the following (a) and (b), 
Postupak proizvodnje Fab’ fragmenta protutijela protiv ljudskog NGF, naznačen time što se sastoji u eksprimiranju Fab’ fragmenta protutijela protiv ljudskog NGF uzgojem stanice domaćina koju se bira iz skupine koju čini sljedeće (a) i (b):
a host cell transformed with an expression vector comprising a polynucleotide comprising a sequence that encodes the heavy-chain fragment of the Fab' fragment according to Claim 2 and a polynucleotide comprising sequence that encodes the light chain of the Fab' fragment according to Claim 2; and 
stanica domaćin transformirana ekspresijskim vektorom koji sadrži polinukleotid koji sadrži slijed koji kodira teškolančani fragment Fab’ fragmenta u skladu s patentnim zahtjevom 2 i polinukleotid koji sadrži slijed koji kodira laki lanac Fab’ fragmenta u skladu s patentnim zahtjevom 2; i
a host cell transformed with an expression vector comprising a polynucleotide comprising a sequence that encodes the heavy-chain fragment of the Fab' fragment according to Claim 2 and with an expression vector comprising a polynucleotide comprising a sequence that encodes the light chain of the Fab' fragment according to Claim 2, and conjugating the anti-human NGF antibody Fab' fragment to polyethylene glycol. 
stanica domaćin transformirana ekspresijskim vektorom koji sadrži polinukleotid koji sadrži slijed koji kodira teškolančani fragment Fab’ fragmenta u skladu s patentnim zahtjevom 2 i ekspresijskim vektorom koji sadrži polinukleotid koji sadrži slijed koji kodira laki lanac Fab’ fragmenta u skladu s patentnim zahtjevom 2, i konjugiranju Fab’ fragmenta protutijela protiv ljudskog NGF s polietilen-glikolom.
A continuous process for preparing polyurea microcapsules with an encapsulation efficiency ≥96% of the active principle, the microcapsules showing a b)/a) ratio, wherein b) is the average diameter determined on 90% of the microcapsules and a) is the average diameter determined on 50% of the microcapsules, comprised between 1.5 and 2.5 whereas the average diameter of 90% of the microcapsules is lower than 15 µm, and encapsulating water insoluble active principles to be used in the pharmaceutical and agrochemical field, the process comprising: 
Kontinuirani postupak pripreme mikrokapsula s učinkovitošću inkapsulacije ≥96% aktivnog sastojka, te mikrokapsule pokazuju omjer b)/a), pri čemu da b) je prosječni promjer određen na 90% mikrokapsula i a) je prosječni promjer određen na 50% mikrokapsula, koji se nalazi između 1.5 i 2.5 dok je prosječni promjer 90% mikrokapsula manji od 15 µm, i inkapsulira water aktivne sastojke netopljive u vodi koji se koriste u farmaceutskom i agrokemijskom području, naznačen time da postupak obuhvaća:
A process according to claim 9, wherein the active principles are selected from the following classes: herbicides, selected from the following classes: 
Postupak prema zahtjevu 9, naznačen time da su aktivni sastojci odabrani iz slijedećih razreda: herbicidi, odabrani iz sljedećih razreda:
alkaline-earth metal salts selected from magnesium chloride, calcium chloride, magnesium nitrate, calcium nitrate, magnesium sulphate; 
soli zemno alkalijskih metala odabrane od magnezijevog klorida, kalcijevog klorida, magnezijevog nitrata, kalcijevog nitrata, magnezijevog sulfata;
An antibody or antigen-binding fragment according to any preceding claim wherein the antibody or fragment comprises a variable light chain (VL) in which CDR1 comprises or consists of the amino acid sequence: 
Protutijelo ili njegov fragment za vezanje antigena koji ima viševalentnu specifičnost vezanja za CD40, pri čemu protutijelo ili fragment sadrži varijabilni laki lanac (VL) u kojem CDR1 sadrži ili se sastoji od sekvence amino kiselina:
is K or H or D or G or N and wherein the antibody or fragment comprises a variable light chain (VL) in which CDR2 comprises or consists of the amino acid sequence: 
je K ili H ili D ili G ili N pri čemu protutijelo ili fragment sadrži varijabilni laki lanac (VL) u kojem CDR2 sadrži ili se sastoji od sekvence amino kiselina:
is G or R and wherein the antibody or fragment a variable light chain (VL) in which CDR3 comprises or consists of the amino acid sequence: 
je G ili R pri čemu protutijelo ili fragment sadrži varijabilni laki lanac (VL) u kojem CDR3 sadrži ili se sastoji od sekvence amino kiselina:
GFTFSTYGMH [SEQ ID NO:28] and wherein the antibody or fragment comprises a variable heavy chain (VH) in which CDR2 comprises or consists of the amino acid sequence of: 
GFTFSTYGMH [SEQ ID NO:28] pri čemu protutijelo ili fragment sadrži varijabilni teški lanac (VH) u kojem CDR2 sadrži ili se sastoji od sekvence amino kiselina:
GKGLEWLSYISGGSSYIFYADSVRGR [SEQ ID NO:29] and wherein the antibody or fragment comprises a variable heavy chain (VH) in which CDR3 comprises or consists of the amino acid sequence of: 
GKGLEWLSYISGGSSYIFYADSVRGR [SEQ ID NO:29] pri čemu protutijelo ili fragment sadrži varijabilni teški lanac (VH) u kojem CDR3 sadrži ili se sastoji od sekvence amino kiselina:
An antibody or antigen-binding fragment or a nucleic acid molecule or a vector or a host cell or a pharmaceutical composition according to Claim 14, wherein the cancer is selected from the group consisting of: prostate cancer; breast cancer; colorectal cancer; pancreatic cancer; ovarian cancer; lung cancer; cervical cancer; rhabdomyosarcoma; neuroblastoma; multiple myeloma; leukemia, acute lymphoblastic leukemia, melanoma, bladder cancer and glioblastoma. 
Protutijelo ili fragment za vezanje antigena ili molekula nukleinske kiseline ili vektor ili stanica domaćina ili farmaceutski pripravak za upotrebu prema zahtjevu 12, naznačen time da se rak bira iz skupine koja sadrži: rak prostate; rak dojke; rak debelog crijeva; rak gušterače; rak jajnika; rak pluća; rak grlića maternice; rabdomiosarkom; neuroblastom; multipli mijelom; leukemiju, akutnu limfoblastnu leukemiju, melanom, rak mokraćnog mjehura i glioblastom.
A method according to claim 1, wherein the fiberising apparatus comprises four rotors. 
Postupak sukladno patentnom zahtjevu 1 ili 2, pri čemu uređaj za izradu vlakana sadrži četiri rotora.
A method according to claim 1, wherein the axes of the first and second rotors are arranged such that a line drawn from the axis of the first rotor to the axis of the second rotor makes an angle of from 0 to 20°, below the horizontal. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 3, pri čemu su osi prvog i drugog rotora raspoređene tako da linija koja se vuče od osi prvog rotora do osi drugog rotora pravi kut od 0 do 20º, ispod vodoravne.
A method according to claim 1, wherein the ratio of the diameter of the last rotor to the diameter of the first rotor is from 1.1:1 to 1.5:1. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 4, pri čemu je odnos promjera zadnjeg rotora prema promjeru prvog rotora od 1,1:1 do 1,5:1.
A method according to claim 1, wherein the first rotor has a diameter of 120 to 250 mm, and the final rotor has a greater diameter of 180 to 330 mm. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 5, pri čemu prvi rotor ima promjer od 120 do 250 mm, i zadnji rotor ima veći promjer od 180 do 330 mm.
A method according to claim 1, wherein the melt is provided on to the periphery of the first rotor at a temperature of 1450 to 1575° C., preferably 1480 to 1550° C. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 8, pri čemu je rastaljeni material postavljen na periferiji prvog rotora na temperaturi od 1450 do 1575ºC, preporučljivo 1480 do 1550ºC.
Glucose isomerase for use according to claim 1 wherein the therapy comprises (a) reducing the bioavailability of fructose in the body of a human or animal or (b) reducing the amount of fructose available to the body of a human or animal or to intestinal bacteria colonizing therein. 
Sredstvo sukladno patentnom zahtjevu 1, naznačeno time da uporaba obuhvaća (a) smanjenje bioraspoloživosti fruktoze u tijelu čovjeka ili životinje ili (b) smanjenje količine fruktoze dostupne ljudskom ili životinjskom tijelu ili na crijevne bakterije koje koloniziraju u njemu nakon uzimanja hrane ili supstance koja sadrži fruktozu.
A method of selecting patients with an addictive disease or disorder who will be responsive to treatment with an antagonist of the serotonin receptor 5-HT3, comprising: 
Metoda odabira bolesnika s bolestima ovisnosti ili poremećajem koji će reagirati na liječenje antagonistom serotoninskog receptora 5-HT3, koji obuhvaća:
A process for upgrading a stream of biogas (2) produced by bacterial digestion of organic residues under anaerobic conditions, comprising at least methane and CO2, to biomethane, said process comprising at least the following steps: 
Postupak prerade struje bioplina (2) proizvedene bakterijskom digestijom organskih ostataka u anaerobnim uvjetima, koja u najmanju ruku sadrži metan i CO2, u biometan, naznačen time što se navedeni postupak u najmanju ruku sastoji u sljedećim koracima:
supplying said electric energy (18) at least to cooling means (R) and producing a cooling fluid (5); 
dostavljanja navedene električne energije (18) u najmanju ruku u hladilo (R) i proizvodnje rashladnog fluida (5);
said heating fluid (3) and said cooling fluid (5) being used for regulating the temperature of said solid sorbents (25). 
navedeni ogrjevni fluid (3) i navedeni rashladni fluid (5) se upotrebljava za reguliranje temperature navedenih čvrstih sorbenata (25).
The process according to the previous claim, wherein the adsorption of said CO2 is effected on said second treatment unit (U2) while the solid sorbent (25) of said first treatment unit (U1) is subjected to regeneration. 
Postupak u skladu s prethodnim patentnim zahtjevom, naznačen time što se adsorbiranje navedenog CO2 provodi u navedenoj drugoj jedinici za obradu (U2) dok se čvrsti sorbent (25) navedene prve jedinice za obradu (U1) podvrgava regeneriranju.
cooling said regenerated solid sorbent. 
hlađenju navedenog regeneriranog čvrstog sorbenta.
The process according to one or more of the previous claims, wherein said treatment system (S) comprises a third treatment unit (U3) comprising at least one solid sorbent (25) and wherein, for at least a certain operating period under regime conditions of said treatment system S, it occurs that: 
Postupak u skladu s jednim ili više prethodnih patentnih zahtjeva, naznačen time što navedeni sustav za obradu (S) sadrži treću jedinicu za obradu (U3), koja sadrži najmanje jedan čvrsti sorbent (25), te što se, u najmanju ruku u izvjesnom periodu rada u režimskim uvjetima navedenog sustava za obradu S, dešava da:
the solid sorbent (25) of a second of said treatment units (U1-U3) is heated to a temperature higher than 60°C and lower than or equal to 120°C so as to form a stream of desorbed CO2 (17'-17"') and a regenerated solid sorbent; 
čvrsti sorbent (25) druge od navedenih jedinica za obradu (U1-U3) se zagrije na temperaturu iznad 60°C, a ispod ili jednaku 120°C, kako bi se dobilo struju desorbiranog CO2 (17'-17'") i regenerirani čvrsti sorbent;
is a group -(CH2)n wherein n is an integer from 2 to 4, 
je skupina -(CH2)n, gdje je n cijeli broj od 2 do 4,
An apparatus (1) for upgrading a stream of biogas (2) produced by bacterial digestion of organic residues under anaerobic conditions, comprising at least methane and CO2, to biomethane, comprising: 
Uređaj (1) za preradu struje bioplina (2) proizvedena bakterijskom digestijom organskih ostataka u anaerobnim uvjetima, koja u najmanju ruku sadrži metan i CO2, u biometan, naznačen time što sadrži:
cooling means (R) for producing a cooling fluid (5) electrically supplied by said cogeneration system (M); 
hladilo (R), namijenjeno proizvodnji rashladnog fluida (5), kojeg električno dostavlja navedeni sustav za kogeneriranje (M);
means for feeding a thermal fluid for supplying said heating fluid (3) or said cooling fluid (5) to at least said treatment units (U1, U2) so as to regulate the temperature of the respective solid sorbents. 
punjač toplinskog fluida, namijenjen dostavljanju navedenog ogrjevnog fluida (3) ili navedenog rashladnog fluida (5) u najmanju ruku navedene jedinice za obradu (U1, U2), radi reguliranja temperature odgovarajućih čvrstih sorbenata.
a main tube (22) through which said heating fluid (3) or said cooling fluid (5) flows, 
glavnu cijev (22), kroz koju teče navedeni ogrjevni fluid (3) ili navedeni rashladni fluid (5),
A method for predicting a therapeutic effect of chemotherapy that uses an antitumor agent comprising a,a,a-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient, the method comprising the steps of: 
Postupak predviđanja terapijskog učinka kemoterapije u kojoj se upotrebljava protutumorsko sredstvo koje sadrži a,a,a-trifluortimidin i 5-klor-6-(1-(2-iminoirolidinil)metil)uracil-hidroklorid u molarnom omjeru od 1:0.5 na pacijentu s kolorektalnim rakom, naznačen time što se postupak sastoji u koracima:
detecting the presence or absence of KRAS gene mutation in a biological sample obtained from the patient; and 
detektiranja prisutnosti ili odsutnosti mutacije u genu KRAS u biološkom uzorku dobivenom iz pacijenta; i
predicting that the patient is likely to sufficiently respond to the chemotherapy, when KRAS gene mutation is detected in Step (1). 
predviđanja da je vjerojatno da će pacijent u dovoljnoj mjeri odgovoriti na kemoterapiju kada se mutaciju u genu KRAS detektira u Koraku (1).
The method according to claim 1 or 2, wherein the colorectal cancer patient is a colorectal cancer patient who is refractory or intolerant to standard therapy. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je pacijent s kolorektalnim rakom pacijent s kolorektalnim rakom koji ne reagira na ili ne podnosi standardnu terapiju.
An antitumor agent for use in the treatment of a colorectal cancer patient with KRAS gene mutation, the antitumor agent comprising a,a,a-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride at a molar ratio of 1:0.5. 
Protutumorsko sredstvo, namijenjeno u potrebi u liječenju pacijenta s kolorektalnim rakom s mutacijom u genu KRAS, naznačeno time što protutumorsko sredstvo sadrži a,a,a-trifluortimidin i 5-klor-6-(1-(2-iminoirolidinil)metil)uracil-hidroklorid u molarnom omjeru od 1:0.5.
a heme-containing protein; and 
protein koji sadrži hem; i
a heme-containing protein; and ii) at least two flavor precursor molecules selected from the group consisting of glucose, fructose, ribose, arabinose, glucose-6-phosphate, fructose 6-phosphate, fructose 1,6-diphosphate, maltose, galactose, lactose, xylose, sucrose, maltodextrin, thiamine, cysteine, cystine, a cysteine sulfoxide, allicin, selenocysteine, methionine, isoleucine, leucine, lysine, phenylalanine, threonine, tryptophan, 5-hydroxytryptophan, valine, arginine, histidine, alanine, asparagine, aspartate, glutamate, glutamine, glycine, proline, serine, tyrosine; wherein after heating said meat substitute and said flavoring composition together, a beef-like flavor is imparted to said meat substitute. 
protein koji sadrži hem; i ii) barem dvije prekursorske molekule okusa odabrane iz skupine koju čine glukoza, fruktoza, riboza, arabinoza, glukoza-6-fosfat, fruktoza 6-fosfat, fruktoza 1,6-difosfat, maltoza, galaktoza, laktoza, ksiloza, saharoza, maltodekstrin, tiamin, cistein, cistin, cistein sulfoksid, alicin, selenocistein, metionin, izoleucin, leucin, lizin, fenilalanin, treonin, triptofan, 5-hidroksitriptofan, valin, arginin, histidin, alanin, asparagin, aspartat, glutamat, glutamin, glicin, prolin, serin i tirozin; naznačen time da se nakon zagrijavanja navedene zamjene za meso i navedenog pripravka za aromu, navedenom nadomjesku za meso daje okus sličan govedini.
The method of claim 11 or 12, wherein the heme-containing protein is a leghemoglobin, preferably a leghemoglobin from soybean, alfalfa, lupin, fava bean, pea, cow pea, or lupine. 
Postupak prema zahtjevu 11 ili 12, naznačen time da protein koji sadrži hem je leghemoglobin, poželjno leghemoglobin z soje, lucerne, lupine, boba, graška, graha metraša, ili lupine.
culturing the one or more cells in the copper supplemented cell culture media such that rA13 is expressed and excreted from the cells into a culture supernatant, wherein the NH4+ content of the cell culture supernatant is maintained at a concentration no more than 5 mM; and 
uzgoja jedne ili više stanica u mediju za uzgoj stanica kompletiranom bakrom, tako da se rVWF eksprimira i izlučuje iz stanica u supernatant kulture, gdje se sadržaj NH4+ u supernatantu kulture stanica održava u koncentraciji ispod 4 mM; i
VLP according to claim 1 or 2, whereas the drug delivery system crosses the blood-brain barrier to enter the CNS together with the drug encapsulated by the VLP. 
VLP za uporabu u skladu s patentnim zahtjevom 1 ili 2, dok VLP prelazi krvno-moždanu barijeru za ulazak u CNS zajedno s lijekom koji je enkapsuliran VLP-om.
Pharmaceutical composition comprising a VLP according to any of the above claims wherein at least 1%. preferably at least 15%, more preferably at least 50%, in particular preferred at least 95% of the total amount of drug substance (cargo) is fully encapsulated in the hull of the VLP. Pharmaceutical composition according to claim 11 wherein the VLP are non-aggregated. 
Farmaceutski pripravak namijenjen uporabi u postupku liječenja terapijom ili metodom in vivo dijagnosticiranja bolesti CNS, dok farmaceutski sastav sadrži VLP prema bilo kojem od gore navedenih zahtjeva, pri čemu najmanje 1%, poželjno najmanje 15%, poželjnije najmanje 50%, naročito poželjno najmanje 95% ukupne količine lijeka potpuno je enkapsulirano u trup VLP-a
A stereolithographic machine according to claim 1, characterized in that said working surfaces (22) are interchangeable and removable from respective support frames. 
Stereolitografski stroj u skladu s patentnim zahtjevom 1, naznačen time, da su navedene radne površine (22) međusobno zamjenjive i uklonjive iz odgovarajućih okvira potpore.
A stereolithographic machine according to one of the previous claims, characterized in that at least one of said working surfaces (22) is parallel to the surface of said vessel (13). 
Stereolitografski stroj u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time što je najmanje jedna od navedenih radnih površina (22) paralelna s površinom navedene posude (13).
A stereolithographic machine according to one of the previous claims, characterized in that said machine comprises means for moving said modeling head (20) according to a direction which is perpendicular with respect to said vessel (13). 
Stereolitografski stroj u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time što navedeni stroj sadrži sredstvo za pomicanje navedene glave za modeliranje (20) u smjeru koji je okomito u odnosu na navedenu posudu (13).
A stereolithographic machine according to one of the previous claims, characterized in that said machine comprises a spatula (24), placed in a longitudinal direction with respect to said vessel (13) and configured to move inside the vessel (13) to clean said vessel (13). 
Stereolitografski stroj u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time što navedeni stroj sadrži lopaticu (24) postavljenu u uzdužnom smjeru u odnosu na navedenu posudu (13) i oblikovanu tako da se unutar posude (13) navedena posuda (13).
A stereolithographic machine according to one of the previous claims, characterized in that said modeling head (22) is shaped as a triangle, preferably an equilateral triangle, and in that said working surfaces (22) are arranged at respective sides of said triangle. 
Stereolitografski stroj u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time što je navedena glava za modeliranje (22) oblikovana kao trokut, poželjno jednakostraničan trokut, i da su navedene radne površine (22) postavljene na odgovarajuće strane navedenog trokuta,